Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic inflammatory diseases, Celltrion USA announced in a press release.A high-concentration ...

The trial included 800 patients with active PsA who hadn’t been treated before with biologic drugs and received either Cosentyx or Humira once a month after weekly lead-in dosing over a 48-week ...